Vericel cell therapy meets in heart failure trial

Vericel Corp. (NASDAQ:VCEL) jumped $1.83 (86%) to $3.95 on Thursday after it said cell therapy ixmyelocel-T met the primary endpoint of significantly reducing clinical cardiac events vs. placebo in the Phase IIb ixCELL-DCM trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM).

Specifically, trans-endocardial catheter-based injections of ixmyelocel-T significantly reduced the number of all-cause deaths, CV hospitalizations or unplanned outpatient and ER visits vs. placebo over the 12 months posttreatment among 114 patients with acute decompensated heart failure. ...